Impact of KRAS Mutation Status on Outcomes in Metastatic Colon Cancer Patients without Anti-Epidermal Growth Factor Receptor Therapy

PURPOSE: Activating mutation of the KRAS oncogene is an established negative predictor for anti-epidermal growth factor receptor (anti-EGFR) therapies in metastatic colorectal cancer (CRC). However, KRAS mutation as a prognostic factor of survival outcome remains controversial in CRC, independent of...

Descripción completa

Detalles Bibliográficos
Autores principales: Kim, Seung Tae, Park, Kyong Hwa, Kim, Jun Suk, Shin, Sang Won, Kim, Yeul Hong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Korean Cancer Association 2013
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3629364/
https://www.ncbi.nlm.nih.gov/pubmed/23613671
http://dx.doi.org/10.4143/crt.2013.45.1.55

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3629364/
https://www.ncbi.nlm.nih.gov/pubmed/23613671
http://dx.doi.org/10.4143/crt.2013.45.1.55

Ejemplares similares